By Gift Briton
The healthcare sector in Kenya is expected to improve and reduce its overreliance on imported vaccines following a joint effort between two institutions that aim to enhance the production of homemade vaccines in the country.
The Kenya Institute of Primate Research(KIPRE) and the Kenya Biovax Institute have come together to promote self-sufficiency in the sector and enhance the security of its vaccine supply.
KIPRE, formerly known as the Institute of Primate Research (IPR), has a rich history of conducting vital research to develop drugs and vaccines for the benefit of the Kenyan population.
These include UNIPRON (a microbicidal contraceptive under development that could prevent transmission of HIV/AIDS and pregnancy), SMUGEL (a water-based and water-soluble lubricant for moisturizing, lubrication, and used in medical procedures) and SMUSCAN (a gel formulated for scanning during ultra-sound services in healthcare facilities).
Furthermore, in response to the urgent need for vaccine production, catalyzed by COVID-19 pandemic, the Kenyan Government established the Kenya Biovax Institute mandated to manufacture, package and commercialize specialized health products and technologies, including vaccines, therapeutics and other biomedical products.
Both institutions have engaged in a series of constructive discussions and negotiations with shared goals of working together to enhance the production and commercialization of healthcare products and services.
KIPRE and Biovax Institute will sign a memorandum of understanding on October 5th October at KIPRE facility to cement this strategic collaboration.
